an approved Investigational New Drug (IND) application or an Investigational Device Exemption (IDE) application, respectively.
Written recommendations for investigation of an orphan drug
The FDA, upon request, will issue written recommendations to the sponsor of an orphan drug for the nonclinical (in vitro and in vivo laboratory animal testing) and clinical drug research and development programs necessary for the drug's approval. This regulatory incentive -initially intended for orphan drugs -has been replaced by the FDA-wide informal consultation process known as the pre-IND program.
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Open protocols for investigation of orphan drugs
The sponsor of an orphan drug under clinical investigation is encouraged to expand the treatment use of the drug to patients who are not eligible to be in the clinical trials and who cannot be satisfactorily treated by available alternative drugs. Such expanded use is governed by the regulations on treatment use protocol of an IND. 8 To initiate such an open protocol, the sponsor must demonstrate to the FDA that (1) the disease or condition is serious or immediately life-threatening, (2) the drug is under active clinical investigation with sufficient evidence of safety and effectiveness, and (3) there is no comparable or satisfactory alternative therapy.
Tax credit
The sponsor of the orphan drug can claim an orphan drug tax credit against federal taxes equal to 50% of the clinical testing expenses incurred between the date the drug is designated as an orphan drug by the FDA and the date of its marketing approval. 9,10 To be eligible, the clinical testing must be conducted under an approved IND. The tax credit may apply to foreign clinical investigation expenses if there is an insufficient testing population in the United States. As currently allowed, the unused tax credit can be carried back one year and then forward 20 years.
Waiver of user fees
In 1992, Congress passed the Prescription Drug User Fee Act authorizing the FDA to collect user fees from drug sponsors to support the costs of drug reviews in exchange for FDA agreement to meet drug-review performance goals in a timely fashion. 11 These fees include the application fee levied on the sponsor's New Drug Application (NDAs) for marketing approval of the drug, the annual establishment fee, and the product fee. Subsequently, the Food and Drug Administration Mod- r a summary of the regulatory history and development status of the drug; and r a statement attesting that the sponsor is the real party of interest in the development, production, and sales of the orphan drug.
The designation request may be submitted to the FDA at any time during the drug-development process, preferably before the commencement of clinical www.cambridge.org © in this web service Cambridge University Press Cambridge University Press 978-0-521-51781-2 -Small Molecule Therapy for Genetic Disease Edited by Jess G. Thoene Excerpt More information investigation to maximize the tax credit benefit. It must, however, be filed before the sponsor submits its own marketing application of the drug. 22 Until such orphan drug is approved, another sponsor may file a separate designation request for the same drug for the same use.
An orphan designation, after being granted, may be revoked only if the FDA later finds material facts that the drug was ineligible for orphan designation at the time the sponsor submitted the request. 23 To protect the sponsor from unpredictable investment risks, the designation status cannot be revoked even if the prevalence of the disease or condition (e.g., because of an outbreak or advancement in diagnosis) subsequently surpasses the threshold of 200,000. 24 At any time before the drug is approved, the sponsor may request an amendment to the designation on the basis of unexpected findings, if such amendment does not render the drug ineligible for orphan designation.
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WHAT IS A MEDICALLY PLAUSIBLE SUBSET?
In general, an orphan designation is granted to a drug intended for use by all patients with a rare disease or condition. Nevertheless, the Orphan Drug Regulations also stipulate that a drug may be designated for use in a defined subset of patients with a common disease or condition, provided that the sponsor can plausibly demonstrate that the drug will be developed for use solely in that subset -in other words, the remaining patients are not appropriate candidates for the drug. 26 The subset is often referred to, in regulatory parlance, as a medically plausible subset.
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Medically plausible subsets have been legitimately defined by the drug's toxicity profile (e.g., a toxic drug to be used in only patients refractory to all lesser toxic treatments); mechanism of action (e.g., a receptor-specific drug for use in receptor-positive patients); unique biopharmaceutical property (e.g., a prodrug requiring metabolic conversion in responders to be effective); route of administration (e.g., an inhalation drug to treat lung-transplant rejection); or previous clinical experiences (e.g., clinical trials showing the drug to be safe and effective in only adult patients). It is reasonable to expect also that a drug targeting a rare genotype-encoded mutation of a common disease phenotype may qualify for orphan designation for the subset of individuals affected by the mutation. In recognizing pediatric patients as "therapeutic orphans," the OOPD has, for years, granted orphan designation to drugs without approved pediatric indication to spur the development of drugs for use in this population.
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HOW DOES THE FDA PROTECT THE MARKETING EXCLUSIVITY OF THE PIONEER DRUG?
Under the Orphan Drug Regulations, two drugs are considered the same if they contain the same active substance (i.e., the active moiety of a small-molecule drug, www.cambridge.org © in this web service Cambridge University Press
29 These regulatory stipulations are solely intended to maximize exclusivity protection to the first approved orphan drug. For example, a second sponsor can neither produce a new salt or an ester form of the same active moiety nor introduce a different glycosylation pattern of a protein drug -a relatively insignificant undertaking in either case -to circumvent the first sponsor's orphan drug exclusivity. Nevertheless, the Orphan Drug Regulations allow orphan designation of a newly developed drug containing the same active substance as a previously approved drug for the same rare disease or condition, if the sponsor of the newly developed drug can present a plausible hypothesis that the former is clinically superior to the latter. 30 This provision was put forth to encourage the development of better orphan drugs and to advance public health. Clinical superiority may be based on greater safety, greater effectiveness, or, when neither can be shown, the drug making a major contribution to patient care. 31 The marketing approval of such a drug, however, is conditioned upon definitive evidence of clinical superiority. If this superiority is proven, the sponsor will receive the seven-year marketing exclusivity for this drug. It is notable that an orphan drug sponsor, despite marketing exclusivity for the orphan indication, may still be vulnerable to marketing competition. This situation may occur when one or more comparable generic versions of the protected drug already exist on the market for other, nonorphan indications. Although the FDA will not permit generic drugs to be labeled for the exclusive orphan indication, the existence of the generic version of the product may not prevent off-label use of the possibly less-expensive versions of the protected drug for the same indication.
OVERVIEW OF NONBIOLOGICAL ORPHAN DRUGS APPROVED FOR GENETIC DISORDERS
As of March 2009, the FDA has approved 24 nonbiological orphan drugs for 21 indications related to genetic disorders (Table 1-1). Sixteen (67%) drugs were considered to be new molecular entities -innovator drugs that had not been previously approved by the FDA for any other uses (Table 1 -2). The prevalence of the diseases or conditions of interest at the time the sponsor made the orphandesignation request ranged from several hundred to 127,000 persons (median ∼15,000). The rate of FDA marketing approval was, on average, one drug per year (Figure 1-1) . The FDA also granted priority review of marketing application to the majority (80%) of these drugs.
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Of the 21 indications, 17 (81%) are for treatment or management of the disease or condition, three (14%) for preventive use, and one (5%) for diagnostic purposes. One drug was concurrently approved for dual indications: desmopressin for treatment of hemophilia A and for von Willebrand disease type I. At the time this chapter was written, seven (32%) orphan drugs still retained orphan drug marketing exclusivity for the orphan indication (Table 1 -2). Of the remaining 15 (68%) drugs with expired exclusivity, 9 (60%) currently have no competitive sources. Among the six drugs with generic counterparts, it is notable that three are relatively costly (epoprostenol -approximately $100,000/year; riluzole -approximately $9,600/year; and desmopressin -approximately $600/dose), two have other approved uses (desmopressin and levocarnitine), and one shares a growing target population (selegiline). 34, 35, 36 The seeming lack of interest by pharmaceutical manufacturers to offer generic versions of relatively unprofitable orphan drugs following the expiration of their exclusivity underlines the need for incentives not only for development, but also for assurance of their long-term marketing availability. The time from orphan designation to marketing approval of the orphan drugs of interest varied greatly, from as short as 4 months 13 days for iloprost to as long as 15 years 2 months for miglustat (Table 1 -2). The median time was approximately three years one month. This length of time may closely approximate how long it took for clinical testing of these drugs , because, for the most part, orphan designation occurred early in the clinical development phase. The actual overall time for a drug-development program (nonclinical and clinical testing) would be substantially longer. As stated earlier, the request for designation must be received by the OOPD prior to the receipt of the NDA by the FDA Review Division of the marketing application of the drug. Several of these drugs were approved for the treatment of manifestations common to both genetic and nongenetic forms of the disease: ambrisentan, bosentan,
